Zosialfa Tablet PR contains Alfuzosin 10 mg, a selective alpha-1 adrenergic receptor antagonist primarily indicated for the treatment of benign prostatic hyperplasia (BPH). Alfuzosin acts by relaxing the smooth muscle in the bladder neck and prostate, thereby improving urine flow and reducing symptoms associated with BPH such as urinary frequency, urgency, and nocturia. The prolonged-release formulation ensures a steady plasma concentration, enhancing therapeutic efficacy while minimizing peak-related side effects. Zosialfa Tablet PR is typically administered once daily, preferably after the same meal each day to optimize absorption. It is contraindicated in patients with hypersensitivity to alfuzosin or other quinazoline derivatives, and caution is advised in individuals with severe hepatic impairment or a history of orthostatic hypotension. Common adverse effects may include dizziness, headache, fatigue, and mild gastrointestinal disturbances. Due to its vasodilatory effects, monitoring blood pressure is recommended, especially during treatment initiation. Zosialfa Tablet PR should be used under medical supervision, with dosage adjustments based on clinical response and tolerability. It is important to inform healthcare providers of any concomitant medications to avoid potential drug interactions, particularly with other alpha-blockers or antihypertensives.